The first data from the SEROQUEL XR™ (quetiapine fumarate) Extended Release clinical development programme in major depressive disorder (MDD)1,2 and generalised anxiety disorder (GAD)3 were presented at the 7th International Forum on Mood and Anxiety Disorders (IFMAD) in Budapest, AstraZeneca announced today. [click link for full article]
Popularity: 1% [?]
Related posts:
- AstraZeneca Presents New Depression And Anxiety Results For SEROQUEL XR
- SEROQUEL XL® (quetiapine Fumarate Prolonged Release): New Depression And Anxiety Results Presented At IFMAD In Budapest
- SEROQUEL XL® (quetiapine Fumarate Prolonged Release): New Depression And Anxiety Results Presented At IFMAD In Budapest
- New Data Presented For SEROQUEL XRTM In Major Depressive Disorder And Generalised Anxiety Disorder
- New Data, New Directions In Management Of Mood And Anxiety Disorders – 8th International Forum For Mood And Anxiety Disorders Congress
Comments
No Responses to “AstraZeneca Presents New Depression And Anxiety Results For SEROQUEL XR”